Advertisement

Topics

Cerecor Inc. Company Profile

10:09 EST 18th December 2018 | BioPortfolio

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving the lives of patients by addressing underserved segments of common diseases. We are focused exclusively on developing products that have human proof-of-concept in either the target or the molecule and possess biomarkers to guide development, and our clinical strategies employ the latest technologies to improve the likelihood of trial success. www.cerecor.com


News Articles [16 Associated News Articles listed on BioPortfolio]

Cerecor to Acquire Ichorion

Includes approximately 5,800,000 shares of Cerecor common stock at closing, and development milestones worth up to $15M

Rare pediatric disease status granted to Cerecor's metabolic disorder drug

Cerecor's substrate replacement therapy CERC-801, being developed to treat patients with inborn error of metabolism, was give -More- 

Cerecor to Acquire Ichorion Therapeutics

Transaction worth approximately $26.6 Million in Stock Plus Potential Milestones Accelerates Cerecor’s Transformation Strategy; Strengthens Rare Disease Pipeline and Expands Pediatric Portfolio B...

Management tracks: Cerecor, Sangamo

Cerecor to Participate in Upcoming Healthcare Conferences

BALTIMORE, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today a...

Cerecor Reports Third Quarter 2018 Results

BALTIMORE, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research a...

Cerecor Announces Expansion of Leadership Team

New Leadership Supports Company Evolution into Innovative Specialty Pharmaceutical Company BALTIMORE, July 16, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), today announced executive manag...

Cerecor CEO to Present at the H.C. Wainwright Global Investment Conference

BALTIMORE, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today an...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Cerecor Inc.

Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving t...

More Information about "Cerecor Inc." on BioPortfolio

We have published hundreds of Cerecor Inc. news stories on BioPortfolio along with dozens of Cerecor Inc. Clinical Trials and PubMed Articles about Cerecor Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cerecor Inc. Companies in our database. You can also find out about relevant Cerecor Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record